Xeris Biopharma Holdings Inc

XERS remains in a Stage 2 advance within its long-term uptrend, driven by an active Parabola pattern signaling strong acceleration. With price extended above rising EMAs and RSI in extreme overbought territory, immediate bullish entries are unfavorable. Preferred engagement is deferred: look for pullbacks into the rising EMA zone as structurally favorable entry points, while remaining vigilant for potential transition risk to Stage 3 distribution.

• ↑Recorlev net revenue surged 95% YoY to $90.3M in Q1 2026
• ↑FY2026 revenue guidance raised to $380–390M on robust demand
• ↓Extremely low book-to-price ratio signals valuation concerns